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eMethods. Calculation of Polygenic Risk Scores and Analyses  
Polygenic risk score 
PRSs were calculated using PRSice v1.25 and PLINK.v.1.9 as the weighted, mean 
number of disorder risk alleles in approximate linkage equilibrium (R2<0.1 within 
1000kb distance), as has been described previously.45 Risk alleles for ADHD and 
ASD were defined as those identified in the most recent combined Psychiatric 
Genomics Consortium (PGC) and iPSYCH analysis of case-control GWAS35,36, at a 
threshold of p<0.05 to maximize phenotypic variance. In brief, the meta-analysis for 
ADHD included 20,183 ADHD cases and 35,191 controls and meta-analysis for 
autism included 18,381 autism cases and 27,969 controls of European ancestry. 
Risk alleles for schizophrenia were identified by the PGC meta-analysis37 including 
34,241 schizophrenia cases and 45,604 controls at a threshold of p<0.05. All 
summary statistics were subject to standard quality control including filtering for 
minor allele frequency (MAF>0.1) and imputation quality (INFO>0.8)46, according to 
an in-house algorithm developed by Richard Anney (https://github.com/ricanney). 
The MHC region on chromosome 6 (26-33Mb) was excluded due to its complex 
linkage disequilibrium (LD) structure. PRS were standardized using z-score 
transformation. Correlations between PRS (p<0.05) were as follows: PRSADHD-
PRSASD r=0.22, PRSADHD-PRSSCZ r=0.05, PRSASD-PRSSCZ r=0.05. For sensitivity 
analysis PRS were derived using various p-value thresholds (p<0.5, p<0.1, p<0.01, 
p<0.005, p<0.001). The number of SNPs included for each threshold and the 
corresponding correlations between PRS are shown in Supplementary Table S1 and 
S2, respectively. 
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Principal Component Analysis (PCA) 
To correct for multiple testing of 32 early-life exposures, the number of independent 
tests was determined based on the number of PCs that explained 80% of covariance 
between the early-life exposures in an unrotated principal component analysis (PCA) 
using the pca function in STATA 13 (see Table S3). We conclude that 21 
independent tests were performed leading to a multiple testing corrected p-value of 
p<0.0024 (0.05/21), which is slightly less conservative than the Bonferroni corrected 
p-value of p<0.0016 (0.05/32), assuming all tests to be independent. 
Inverse probability weighting 
PRS for ADHD and schizophrenia have been shown to be highly associated with 
attrition in the ALSPAC core study52 and a comparison between the study sample 
with (n=7,486) and without (n=6,307) genetic data available suggests that they differ 
in many of the analysed factors, especially those that relate to socio-economic status 
(Table S2). As sensitivity analysis, we performed an inverse probability weighting on 
missing maternal genetic data. Weights were derived from a logistic regression 
model for missingness including variables with <1% missing data (child sex, 
birthweight and maternal age at delivery) in the ALSPAC core study. Missing data for 
maternal age at delivery was imputed as the mean value. Weights ranged from 1.36 
to 3.03. 
Observational associations 
ADHD was defined as score of more or equal to 7 on the 5 items hyperactivity 
subscale of the Strength and Difficulties Questionnaire (SDQ) at age 7. ASD was 
defined as either a) being diagnosed with Pervasive Developmental Disorder using 
questions from the DAWBA questionnaire at 91months or b) the mother’s answer to 
© 2019 Leppert B et al. JAMA Psychiatry. 
the question “Have you ever been told that your child has autism, Asperger’s 
syndrome or autistic spectrum disorder?” at age 9 or c) a diagnosis of autism 
spectrum disorder using the ICD-10 criteria from a review of all children given a 
statement for special educational provision in the Avon area [1].  
Risk ratios (RR) for the investigated early life exposures were assessed using 
general linear models (glm) with logit-link and Poisson distribution, adjusted for sex 
and age at ADHD/ASD assessment.  
1 Williams E, Thomas K, Sidebotham H, Emond A. Prevalence and characteristics of autistic 
spectrum disorders in the ALSPAC cohort. Dev Med Child Neurol. 2008 Sep; 50(9):672-7. 
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eTables 
eTable 1. Number of SNPs Used to Calculate the Polygenic Risk Scores (PRS) for 
ADHD, ASD, and Schizophrenia 
 Number of SNPs used to calculate: 
p-value threshold PRSADHD PRSASD PRSSCZ 
0.5 76371 102902 79956 
0.1 29240 37678 35564 
0.05 18475 23085 24367 
0.01 6156 7040 10165 
0.005 3800 4135 7014 
0.001 1303 1259 3075 
5x10-8 16 12 108 
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eTable 2. Correlation (r) of Polygenic Risk Scores (PRS) for ADHD, ASD, and 
Schizophrenia 
P value threshold .50 .10 .05 .01 .005 .001 
a) PRSADHD 
0.5 1      
0.1 0.90 1     
0.05 0.83 0.92 1    
0.01 0.64 0.71 0.77 1   
0.005 0.55 0.61 0.66 0.87 1  
0.001 0.39 0.43 0.47 0.61 0.71 1 
b) PRSASD 
0.5 1      
0.1 0.89 1     
0.05 0.82 0.91 1    
0.01 0.82 0.91 1 1   
0.005 0.53 0.59 0.64 0.64 1  
0.001 0.36 0.40 0.44 0.44 0.66 1 
c) PRSSCZ 
0.5 1      
0.1 0.93 1     
0.05 0.88 0.94 1    
0.01 0.75 0.80 0.85 1   
0.005 0.69 0.74 0.78 0.92 1  
0.001 0.55 0.59 0.64 0.75 0.82 1 
d) PRS correlation across disorders* 
p-value threshold 0.5 0.1 0.05 0.01 0.005 0.001 
1) Correlation with PRSADHD 
PRSASD 0.26 0.24 0.22 0.17 0.12 0.08 
PRSSCZ 0.05 0.05 0.05 0.05 0.05 0.04 
2) Correlation with PRSASD 
PRSSCZ 0.06 0.06 0.05 0.04 0.01 0.01 
*with same p-value threshold 
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eTable 3. Principal Component Analysis of Outcomes to Determine the Number of 
Independent Tests  
Component Eigenvalue Difference Proportion Cumulative 
Comp1 2.41 0.14 0.07 0.07 
Comp2 2.27 0.35 0.07 0.14 
Comp3 1.92 0.19 0.06 0.20 
Comp4 1.73 0.06 0.05 0.25 
Comp5 1.67 0.14 0.05 0.30 
Comp6 1.53 0.21 0.05 0.35 
Comp7 1.31 0.01 0.04 0.39 
Comp8 1.30 0.12 0.04 0.43 
Comp9 1.18 0.05 0.04 0.46 
Comp10 1.13 0.01 0.03 0.50 
Comp11 1.12 0.05 0.03 0.53 
Comp12 1.07 0.04 0.03 0.57 
Comp13 1.03 0.03 0.03 0.60 
Comp14 1.00 0.03 0.03 0.63 
Comp15 0.98 0.01 0.03 0.66 
Comp16 0.96 0.05 0.03 0.69 
Comp17 0.92 0.02 0.03 0.71 
Comp18 0.90 0.06 0.03 0.74 
Comp19 0.84 0.01 0.03 0.77 
Comp20 0.83 0.07 0.03 0.79 
Comp21 0.76 0.01 0.02 0.81 
Comp22 0.75 0.05 0.02 0.84 
Comp23 0.70 0.03 0.02 0.86 
Comp24 0.67 0.02 0.02 0.88 
Comp25 0.66 0.05 0.02 0.90 
Comp26 0.61 0.01 0.02 0.92 
Comp27 0.60 0.04 0.02 0.93 
Comp28 0.56 0.07 0.02 0.95 
Comp29 0.50 0.05 0.02 0.97 
Comp30 0.45 0.05 0.01 0.98 
Comp31 0.40 0.16 0.01 0.99 
Comp32 0.24 0.24 0.01 1.00 
(unrotated rho=1, observations n=615)  
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eTable 4. Comparison of Study Sample With and Without Available Genetics Data 
 With genetic data Without genetic data 
t Test 
 Mean SD N  Mean SD N 
Age at delivery 28.5 0.06 7486 27.4 0.06 6307 <.001 
Stressful life event score 3.5 0.03 6695 3.5 0.04 4974 .889 
Vitamin D (25OHD) [nmol/l] 67.6 0.46 4793 65.7 0.6 3017 .014 
BMI (pre-pregnancy) 22.9 0.05 6516 22.9 0.06 4867 .817 
Selenium (Se) [µg/l] 112 0.47 2625 111 0.65 1454 .030 
Mercury (Hg) [µg/l] 2.12 0.02 2535 2.01 0.03 1396 .002 
Cadmium (Cd) [µg/l] 0.52 0.01 2624 0.63 0.02 1451 <.001 
Lead (Pb) [µg/l] 3.65 0.03 2624 3.71 0.04 1450 .212 
 N(Yes) N(No) N(total) N(Yes) N(No) N(total) χ2 Test 
Smoking 1706 5148 6854 1837 3456 5293 <.001 
Alcohol consumption 4312 1558 5900 3173 1061 4234 .036 
Binge drinking at 1st trimester 1165 5968 7133 1016 4641 5657 .015 
Breast fed their child 5562 1344 6906 3827 1447 5274 <.001 
Taking iron supplements 1447 5662 7139 1400 4317 5717 <0.001 
Taking zinc supplements 91 7048 7139 72 5643 5715 .940 
Taking folic acid supplements 643 6489 7132 505 5206 5711 .733 
Taking vitamin supplements 1166 5956 7122 929 4763 5692 .939 
Taking paracetamol 3838 3304 7142 3182 2548 5730 .042 
Taking antidepressants 58 7095 7153 66 5649 5715 .047 
Ever had diabetes 68 7351 7419 39 6117 6156 .063 
Gestational Diabetes 35 6615 6650 21 5084 5105 .37 
Ever had hypertension 984 5822 6806 799 4453 5252 .247 
Gestational hypertension 1058 6201 7259 869 5157 6026 .802 
Preeclampsia 160 7259 7149 130 6026 6156 .857 
Vaginal bleeding 1198 5561 6759 881 4327 5208 .247 
Any infection 1476 5207 6683 1169 3793 4962 .061 
Ever had rheumatism 295 6522 6817 228 4991 5219 .912 
Ever had psoriasis 256 6537 6793 158 5039 5197 .030 
Ever had depression 539 6308 6847 566 4694 5260 <.001 
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eTable 5. Association of Maternal Polygenic Risk Scores (PRS) for ADHD, ASD, and Schizophrenia (P < .05) With Maternal Age at 
Delivery 
  
 
PRSADHD  PRSASD  PRSSCZ 
  N  OR 95% CI P value  OR 95% CI P value  OR 95% CI P value 
Maternal age 
22 years and younger  768  1.32 1.22, 1.43 1 × 10-11  0.96 0.89, 1.04 .298  0.95 0.87, 1.03 .186 
23 – 27 years  2381  1.12 1.06, 1.18 6 × 10-5  0.95 0.90, 1.00 .052  0.94 0.89, 1.00 .035 
33 – 37 years  1212  0.98 0.91, 1.05 .538  1.01 0.94, 1.07 .879  0.94 0.88, 1.01 .086 
38 years and older  256  0.89 0.79, 1.02 .088  1.02 0.90, 1.16 .769  1.06 0.93, 1.20 .407 
Estimates from multinomial logistic regression with reference group for maternal age being 28-32 years (N=2869)  
ADHD attention deficit/hyperactivity disorder, OR odds ratio, CI confidence interval  
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eTable 6. Association of Maternal Polygenic Risk Scores (PRS) (P < .05) With Prenatal Exposures Linked to Offspring 
Neurodevelopmental Disorders 
  PRSADHD  PRSASD  PRSSCZ 
  OR 95% CI P value  OR 95% CI P value  OR 95% CI P value 
Smoking  1.26 1.20, 1.32 3 × 10-22  1.03 0.98, 1.08 .230  1.11 1.06, 1.16 1 × 10-5 
Alcohol consumption  1.00 0.92, 1.08 .913  1.02 0.94, 1.11 .604  1.04 0.95, 1.13 .413 
Binge drinking during 1st trimester  1.10 1.05, 1.16 1 × 10-4  1.06 1.00, 1.11 .035  1.09 1.04, 1.15 .001 
Taking iron supplements  0.98 0.93, 1.03 .371  1.00 0.95, 1.05 .979  1.09 1.03, 1.14 .001 
Taking zinc supplements  0.97 0.3, 1.13 .689  0.99 0.84, 1.15 .855  1.23 1.05, 1.44 .009 
Taking folic acid supplements  0.98 0.92, 1.04 .526  1.06 0.99, 1.13 .087  1.11 1.04, 1.19 .001 
Taking vitamins supplements  0.92 0.77, 1.10 .347  0.89 0.75, 1.06 .203  1.05 0.88, 1.25 .597 
Taking paracetamol  1.09 1.04, 1.15 .001  1.00 0.95, 1.06 .891  0.97 0.92, 1.02 .256 
Taking antidepressants  1.06 0.88, 1.27 .563  1.08 0.89, 1.30 .448  1.03 0.85, 1.24 .748 
Ever had diabetes  1.30 1.09, 1.55 .004  1.05 0.87, 1.25 .615  0.89 0.74, 1.06 .191 
Gestational diabetes  1.50 1.17, 1.92 .001  1.01 0.79, 1.30 .933  1.08 0.84, 1.38 .563 
Ever had hypertension  1.06 1.00, 1.01 .046  1.01 0.96, 1.07 .604  1.07 1.01, 1.13 .023 
Gestational hypertension  0.97 0.92, 1.02 .267  0.99 0.94, 1.05 .771  1.04 0.99, 1.10 .120 
Preeclampsia  1.09 0.97, 1.22 .148  1.19 1.06, 1.34 .003  1.08 0.96, 1.21 .208 
Vaginal bleeding  1.03 0.98, 1.08 .293  1.01 0.96, 1.06 .692  1.07 1.02, 1.13 .008 
Any infection  1.12 1.07, 1.17 6 × 10-6  1.06 1.01, 1.11 .017  1.04 0.99, 1.09 .163 
Ever had rheumatism  1.04 0.85, 1.14 .351  1.10 1.01, 1.20 .033  1.03 0.94, 1.13 .510 
Ever had psoriasis  0.99 0.90, 1.09 .809  1.02 0.93, 1.12 .639  1.04 0.94, 1.14 .440 
Ever had severe depression  1.22 1.14, 1.31 1 × 10-8  1.12 1.05, 1.20 .001  1.21 1.13, 1.30 6 × 10-8 
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  PRSADHD  PRSASD  PRSSCZ 
  β 95% CI P value  β 95% CI P value  β 95% CI P value 
BMI (pre-pregnancy)  0.27 0.17, 0.36 1 × 10-8  -0.02 -0.11, 0.07 .691  -0.16 -0.25, -0.07 .001 
Age at delivery  -0.43 -0.54, -0.33 3 × 10-15  0.10 -0.01, 0.20 .084  0.04 -0.06, 0.15 .426 
Stressful life event score in 1st trimester  0.08 0.03, 0.14 .005  0.08 0.02, 0.14 .005  0.05 -0.01, 0.11 .112 
Vitamin D (OHD)*  0.00 -0.01, 0.01 .991  -0.01 -0.02, 0.01 .300  0.11 0.00, 0.03 .097 
Selenium (Se)*  -0.01 -0.02, -0.01 7 × 10-4  0.00 -0.01, 0.01 .929  0.00 0.00, 0.01 .367 
Mercury (Hg)  -0.07 -0.11, -0.02 0.002  0.01 -0.03, 0.06 0.506  0.02 -0.02, 0.06 0.297 
Cadmium (Cd)  0.07 0.05, 0.09 7x10-10  0.01 -0.01, 0.03 0.455  0.03 0.00, 0.05 0.019 
Lead (Pb)  -0.03 -0.08, 0.03 0.361  0.02 -0.03, 0.08 0.385  -0.01 -0.07, 0.04 0.642 
ADHD attention deficit/hyperactivity disorder, β beta coefficients, CI confidence interval, * log transformed 
Analysis uses IPW to account for study population attrition.   
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eTable 7. Association of Maternal Polygenic Risk Scores (PRS) (P < .05) With Perinatal Exposures and Conditions Linked to 
Offspring Neurodevelopmental Disorders 
  PRSADHD  PRSASD  PRSSCZ 
  OR 95% CI P value  OR 95% CI P value  OR 95% CI P value 
C-Section  1.00 0.95, 1.06 .888  1.02 0.96, 1.08 .460  0.96 0.90, 1.01 .132 
Low birthweight (<2500g)  0.88 0.60, 1.30 .527  0.99 0.68, 1.43 .947  1.02 0.72, 1.43 .916 
Preterm delivery (<37weeks)  0.99 0.92, 1.07 .814  0.97 0.90, 1.04 .351  0.95 0.89, 1.03 .226 
Hypoxia  1.05 0.99, 1.11 .083  1.03 0.98, 1.09 .229  1.02 0.96, 1.08 .561 
Low Apgar at 1 minute  1.12 1.04, 1.20 .002  1.02 0.95, 1.09 .587  1.00 0.93, 1.08 .974 
Low Apgar at 5 minutes  1.06 0.86, 1.30 .579  1.07 0.87, 1.31 .536  0.76 0.62, 0.94 .012 
Breast fed their child  0.87 0.79, 0.96 .004  1.04 0.94, 1.11 .460  1.04 0.95, 1.15 .416 
ADHD attention deficit/hyperactivity disorder, OR odds ratio, CI confidence interval 
Analysis uses IPW to account for study population attrition.
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eTable 8. Association of Early Life Exposure With Observed ADHD and ASD Symptoms in ALSPAC 
 ADHD ASD 
 RR 95% CI P value Nyes NNo RR 95% CI P value Nyes NNo 
Smoking 1.70 1.37,2.10 1 × 10-6 1,666 5,923 0.77 0.45,1.30 .327 1,657 6,100 
Alcohol consumption 1.42 1.09,1.85 .009 4,610 1,661 1.21 0.72,2.04 .467 4,721 1,699 
Binge drinking* 1.35 1.05,1.72 .017 1,198 6,471 0.80 0.44,1.45 .465 1,202 6,669 
Taking iron supplements 1.01 0.79,1.28 .958 1,576 6,099 1.28 0.81,2.03 .295 1,616 6,275 
Taking zinc supplements 0.85 0.36,2.01 .716 108 7,569 0.67 0.09,4.94 .697 112 7,782 
Taking folic acid supplements 0.87 0.62,1.23 .445 723 6,947 1.59 0.89,2.83 .116 727 7,161 
Taking vitamins supplements 1.00 0.99,1.02 .670 1,305 6,351 1.13 0.58,1.88 .639 1,347 6,526 
Taking paracetamol 1.45 1.18,1.78 4 × 10-4 4,585 3,000 0.76 0.51,1.13 .181 4,717 3,069 
Taking antidepressants 0.69 0.16,2.97 .616 45 7,633 1.59 0.21,12.06 .652 47 7,844 
Ever had diabetes 2.74 1.24,6.06 .013 58 7,743 4.35 1.49,12.67 .007 73 7,961 
Gestational diabetes 2.57 0.90,7.36 .079 33 7,317 1.66 0.22,12.59 .626 42 7,491 
Ever had hypertension 0.84 0.62,1.12 .232 1,069 6,450 0.33 0.13,0.82 .017 1,090 6,608 
Gestational hypertension 1.14 0.88,1.48 .330 1,116 6,534 1.28 0.75,2.18 .369 1,127 6,748 
Preeclampsia 1.07 0.54,2.10 .848 151 7,650 3.13 1.32,7.43 .010 159 7,875 
Vaginal bleeding 1.05 0.81,1.37 .712 1,261 5,970 0.79 0.43,1.43 .429 1,311 6,120 
Any infection 1.25 0.99,1.57 .056 1,567 5,959 0.87 0.51,1.48 .601 1,578 6,116 
Ever had rheumatism 0.97 0.59,1.59 .913 318 7,198 1.29 0.51,3.24 .586 325 7,377 
Ever had psoriasis 1.29 0.79,2.11 .307 262 7,223 1.15 0.41,3.18 793 268 7,404 
Ever had severe depression 1.64 1.20,2.25 .002 589 6,966 0.96 0.44,2.09 0.912 572 7,171 
 
 ADHD ASD 
© 2019 Leppert B et al. JAMA Psychiatry. 
 RR 95% CI P value Nyes NNo RR 95% CI P value Nyes NNo 
BMI (pre-pregnancy) 1.01 0.99,1.04 .272 - 7,173 0.98 0.92,1.04 .561 - 7,343 
Age at delivery 0.97 0.95,0.99 .004 - 7,833 1.03 0.99,1.08 .123 - 8,069 
Stressful life event score 1.15 1.10,1.20 2 × 10-9 - 6,941 0.95 0.85,1.06 .325 - 7,088 
Vitamin D (OHD)* 0.89 0.68,1.15 .361 - 4,546 1.11 0.66,1.88 .687 - 4,722 
Selenium (Se)* 0.87 0.35,2.14 .759 - 2,418 1.73 0.29,10.41 .548 - 2,457 
Mercury (Hg) 0.80 0.66,0.98 .029 - 2,330 0.89 0.64,1.14 .282 - 2,370 
Cadmium (Cd) 1.40 1.06,1.83 .017 - 2,418 1.33 0.77,2.29 .314 - 2,457 
Lead (Pb) 1.00 0.89,1.12 .987 - 2,416 0.85 0.64,1.14 .282 - 2,455 
C-Section 1.09 0.80,1.47 .600 791 6,887 0.53 0.23,1.21 .132 820 7,083 
Low birthweight (<2500g) 1.17 0.86,1.65 .416 314 7,424 1.20 0.72,2.40 .628 323 7,656 
Preterm delivery (<37weeks) 1.40 0.95,2.07 .090 378 7,455 0.94 0.38,2.34 .888 400 7,669 
Hypoxia 1.13 0.87,1.46 .358 1,306 3,304 0.81 0.46,1.41 .449 1,354 3,397 
Low Apgar at 1 minute 1.50 1.08,2.07 .015 562 4,043 1.68 0.90,3.14 .101 583 4,166 
* at 18 weeks of gestation 
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eTable 9. Association of Maternal Polygenic Risk Scores (P < .05) With Maternal Alcohol Consumption, Smoking Behavior, and 
Stressful Life Events at Different Time Intervals During and Before Pregnancy 
   ADHD  ASD  Schizophrenia 
 N (No) N (Yes) N (Total)  OR 95% CI P value  OR 95% CI P value  OR 95% CI P value 
Maternal alcohol consumption 
before pregnancy 491 6804 7295  0.89 0.63, 1.28 .540  0.99 0.68, 1.43 .945  1.02 0.70, 1.48 .918 
during 1st trimester 3225 4051 7276  0.99 0.92, 1.06 .764  1.00 0.94, 1.08 .914  1.01 0.94, 1.08 .854 
during 3rd trimester 2829 1526 4355  0.91 0.84, 0.98 .015  1.05 0.97, 1.13 .218  1.05 0.97, 1.13 .261 
during pregnancy 1620 4385 6005  0.99 0.89, 1.11 .907  1.02 0.92, 1.14 .696  1.03 0.92, 1.15 .594 
Maternal Smoking 
before pregnancy 5073 2257 7330  1.24 1.17, 1.32 1x10-12  1.03 0.97, 1.10 .303  1.11 1.05, 1.18 .001 
during 1st trimester 5710 1620 7330  1.25 1.17, 1.33 1x10-11  1.04 0.98, 1.11 .184  1.14 1.04, 1.18 .001 
during 3rd trimester 5630 1157 6787  1.27 1.18, 1.36 6x10-11  1.06 0.99, 1.14 .086  1.06 0.99, 1.14 .082 
during pregnancy 5205 1746 6951  1.27 1.19, 1.35 3x10-13  1.03 0.97, 1.10 .297  1.11 1.04, 1.18 .001 
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eTable 10. Association of Maternal Polygenic Risk Scores (PRS) (P < .05) With Prenatal Exposures Linked to Offspring 
Neurodevelopmental Disorders, Excluding Mothers Who Have Reported Taking Medication for Anxiety, Depression, Migraine, 
Sleeping Problem, or Other* 
  PRSADHD  PRSASD  PRSSCZ 
 Ntotal OR 95% CI P value  OR 95% CI P value  OR 95% CI P value 
Smoking 4926 1.26 1.16,1.36 5 × 10-9  1.00 0.93,1.08 .964  1.12 1.04,1.21 .003 
Alcohol consumption 4208 1.00 0.88,1.13 .987  1.02 0.90,1.15 .781  1.03 0.91,1.17 .636 
Binge drinking during 1st trimester 5114 1.08 0.99,1.17 .073  1.01 0.93,1.10 .826  1.04 0.96,1.13 .340 
Taking iron supplements 5117 0.94 0.87,1.02 .120  0.96 0.89,1.03 .280  1.10 1.02,1.19 .018 
Taking zinc supplements 5117 0.86 0.67,1.11 .248  0.93 0.72,1.21 .598  1.22 0.94,1.57 .135 
Taking folic acid supplements 5110 0.93 0.84,1.03 .177  1.01 0.91,1.11 .918  1.14 1.03,1.26 .011 
Taking vitamins supplements 5104 0.94 0.87,1.02 166  0.96 0.89,1.04 .360  1.11 1.02,1.20 .016 
Taking paracetamol 4983 1.12 1.03,1.21 .008  1.00 0.92,1.08 .909  0.98 0.91,1.06 .654 
Ever had diabetes 5399 1.37 1.01,1.85 .041  1.02 0.75,1.37 .909  0.88 0.65,1.19 .395 
Gestational diabetes 4813 1.59 1.03,2.46 .037  1.07 0.70,1.63 .754  0.98 0.63,1.51 .921 
Ever had hypertension 4919 1.05 0.96,1.14 .331  1.02 0.94,1.12 .613  1.08 0.98,1.18 .106 
Gestational hypertension 5281 0.97 0.90,1.06 .541  1.00 0.92,1.09 .955  1.03 0.95,1.12 .499 
Preeclampsia 5399 1.14 0.95,1.38 .159  1.23 1.02,1.48 .028  1.08 0.90,1.30 .415 
Vaginal bleeding 4836 1.05 0.96,1.14 .267  1.02 0.94,1.10 .720  1.08 1.00,1.18 .058 
Any infection 4839 1.10 1.02,1.19 .018  1.05 0.97,1.13 .224  1.02 0.94,1.10 .652 
Ever had rheumatism 4941 0.95 0.82,1.11 .523  0.96 0.82,1.11 .577  1.00 0.85,1.16 .966 
Ever had psoriasis 4929 1.02 0.88,1.19 .791  1.10 0.95,1.28 .210  1.03 0.88,1.20 .693 
Ever had severe depression 4965 1.19 1.06,1.34 .003  1.04 0.93,1.16 .546  1.26 1.13,1.42 
6 × 10-
5 
* other medication that was not used for nausea, heartburn, vomiting, infection, pain, allergies, skin condition, bleeding, piles, constipation and cough 
ADHD attention deficit/hyperactivity disorder, OR odds ratio, CI confidence interval  
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eTable 10 (continued) 
  PRSADHD  PRSASD  PRSSCZ 
 Ntotal β 95% CI P value  β 95% CI P value  β 95% CI P value 
BMI (pre-pregnancy) 4719 0.25 0.14,0.35 5 × 10-6  0.01 -0.09,0.11 .850  -0.20 -0.31,-0.09 2 × 10-4 
Age at delivery 5454 -0.44 -0.57,-0.31 
1 × 10-
11 
 0.09 -0.03,0.22 .143  0.08 -0.05,0.20 .249 
Stressful life event score in 1st trimester 4847 0.04 -0.03,0.11 .223  0.07 0.01,0.14 .033  0.04 -0.03,0.11 .257 
Vitamin D (OHD)* 3486 0.00 -0.01,0.02 .882  -0.01 -0.02,0.01 .340  0.01 -0.01,0.02 .292 
Selenium (Se)* 1903 -0.01 -0.02,0.00 .005  -0.004 -0.01,0.004 .315  0.00 -0.01,0.01 .745 
Mercury (Hg) 1838 -0.06 -0.11,-0.01 .023  0.02 -0.03,0.07 .511  0.04 -0.02,0.09 .169 
Cadmium (Cd) 1903 0.06 0.03,0.08 2 × 10-5  0.01 -0.02,0.04 .440  0.03 0.00,0.05 .047 
Lead (Pb) 1903 -0.01 -0.07,0.06 .799  0.03 -0.04,0.09 .430  -0.01 -0.08,0.05 .702 
ADHD attention deficit/hyperactivity disorder, β beta coefficients, CI confidence interval, * log transformed   
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eTable 10 (continued) 
  PRSADHD  PRSASD  PRSSCZ 
 Ntotal OR 95% CI P value  OR 95% CI P value  OR 95% CI P value 
C-Section 5326 1.03 0.94,1.13 .519  1.04 0.95,1.14 .436  0.96 0.87,1.05 .359 
Low birthweight (<2500g) 5378 0.84 0.41,1.74 .640  0.99 0.52,1.86 .967  0.97 0.52,1.81 .912 
Preterm delivery (<37weeks) 5454 1.03 0.91,1.16 .671  0.98 0.87,1.11 .800  0.98 0.87,1.11 .754 
Hypoxia 3178 1.12 1.02,1.23 .018  1.07 0.98,1.17 .144  1.06 0.96,1.16 .248 
Low Apgar at 1 minute 3177 1.16 1.04,1.30 .011  1.08 0.96,1.21 .191  1.04 0.93,1.16 .509 
Low Apgar at 5 minutes 3173 1.28 0.90,1.81 .167  1.24 0.88,1.75 .222  0.84 0.59,1.20 .344 
Breast fed their child 5009 0.86 0.73,1.01 .071  1.03 0.88,1.21 .703  1.05 0.89,1.24 .545 
ADHD attention deficit/hyperactivity disorder, OR odds ratio, CI confidence interval
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eFigure 1. Association of Maternal Polygenic Risk Scores for ADHD at Different P Value Thresholds With Prenatal and Perinatal 
Exposures Linked to Offspring Neurodevelopmental Disorders  
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eFigure 2. Association of Maternal Polygenic Risk Scores for ADHD at Different P Value Thresholds With Prenatal and Perinatal 
Exposures Linked to Offspring Neurodevelopmental Disorders  
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eFigure 3. Association of Maternal Polygenic Risk Scores for Autism at Different P Value Thresholds With Prenatal and Perinatal 
Exposures Linked to Offspring Neurodevelopmental Disorders  
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eFigure 4. Association of Maternal Polygenic Risk Scores for Autism at Different P Value Thresholds With Prenatal and Perinatal 
Exposures Linked to Offspring Neurodevelopmental Disorders  
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eFigure 5. Association of Maternal Polygenic Risk Scores for Schizophrenia at Different P Value Thresholds With Prenatal and 
Perinatal Exposures Linked to Offspring Neurodevelopmental Disorders  
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eFigure 6. Association of Maternal Polygenic Risk Scores for Schizophrenia at Different P Value Thresholds With Prenatal and 
Perinatal Exposures Linked to Offspring Neurodevelopmental Disorders 
